万东医疗(600055) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥392,997,329.14, representing an increase of 18.57% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥30,991,596.41, a decrease of 29.79% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,020,301.79, down 13.71% from the previous year[2]. - Total operating revenue for the first three quarters of 2024 reached CNY 1,093,084,824.41, an increase of 18.1% compared to CNY 925,789,900.33 in the same period of 2023[14]. - Net profit for the third quarter of 2024 was CNY 116,626,283.67, a decrease of 4.9% from CNY 121,823,300.98 in the same quarter of 2023[15]. - Basic and diluted earnings per share for Q3 2024 were both CNY 0.165, slightly down from CNY 0.171 in Q3 2023[16]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥5,333,855,627.01, a decrease of 1.16% from the end of the previous year[3]. - The total assets of Beijing Wandong Medical Technology Co., Ltd. as of September 30, 2024, amounted to CNY 5,333,855,627.01, a slight decrease from CNY 5,396,325,530.54 at the end of 2023[10]. - The company's total liabilities decreased to CNY 484,350,240.72 from CNY 575,700,678.51 year-over-year, reflecting a reduction of 15.9%[12]. - The total equity attributable to shareholders at the end of Q3 2024 was ¥4,739,461,274.00, an increase of 0.59% from the end of the previous year[3]. - The total equity attributable to shareholders of the parent company increased to CNY 4,739,461,274.00, up from CNY 4,711,473,658.91, representing a growth of 0.6%[13]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥25,376,678.78, down 45.79% year-on-year[2]. - The company's cash flow from operating activities decreased significantly due to reduced sales collections from subsidiaries[6]. - Cash inflow from operating activities for the first three quarters of 2024 was CNY 1,141,789,099.03, down from CNY 1,183,299,855.74 in the same period of 2023, indicating a decline of approximately 3.5%[16]. - Net cash flow from operating activities for the first three quarters of 2024 was CNY 25,376,678.78, significantly lower than CNY 46,814,270.40 in the previous year[16]. - Cash inflow from investment activities for Q3 2024 totaled CNY 589,096,890.44, compared to CNY 850,587,310.47 in Q3 2023, marking a decrease of about 30.7%[17]. - Net cash flow from investment activities for Q3 2024 was -CNY 466,001,126.70, compared to -CNY 413,747,838.88 in Q3 2023, indicating a worsening of investment cash flow[17]. - Cash outflow from financing activities for Q3 2024 was CNY 93,756,378.08, compared to CNY 87,189,830.68 in Q3 2023, showing an increase in financing costs[17]. Expenses - Total operating costs for the first three quarters of 2024 were CNY 973,078,073.01, up 17.9% from CNY 825,712,758.90 in the previous year[14]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 115,518,473.81, an increase of 5.3% compared to CNY 109,772,089.94 in the same period of 2023[14]. - Employee compensation payments increased to CNY 279,072,049.27 in Q3 2024, compared to CNY 234,336,618.23 in Q3 2023, reflecting a rise of approximately 19%[16]. Shareholder Information - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[9]. - There are no significant changes in the shareholder structure or related party transactions reported for the period[9]. Future Outlook - Future outlook includes continued investment in new technologies and market expansion strategies to enhance growth potential[15].